Targeting iron uptake as a new therapeutic option for ANKL. ANKL cells primarily engraft and proliferate in the liver sinusoid. The liver stores iron, and ANKL cells upregulate the TfR1 to take up iron-loaded transferrin. Inhibiting TfR1 by the monoclonal blocking antibody PPMX-T003 lowers iron import and deprives ANKL cells of their iron content, reducing their survival and/or proliferation. Figure created with BioRender.com.